enow.com Web Search

  1. Ads

    related to: long acting insulin brands

Search results

  1. Results from the WOW.Com Content Network
  2. Insulin glargine - Wikipedia

    en.wikipedia.org/wiki/Insulin_glargine

    Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type 1 and type 2 diabetes. [7] It is injected just under the skin . [ 7 ]

  3. Ultralente insulin - Wikipedia

    en.wikipedia.org/wiki/Ultralente_insulin

    Ultralente insulin was a long-acting form of insulin. It has an onset of 4 to 6 hours, a peak of 14 to 24 hours, and a duration of 28 to 36 hours. [ 1 ] Ultralente insulin, along with lente insulin , were discontinued in the US by manufacturers in the mid-2000s.

  4. Insulin degludec - Wikipedia

    en.wikipedia.org/wiki/Insulin_degludec

    This cannot be done using other long-acting insulins. [19] [20] A physician involved in the trials was quoted as saying, This allows the creation of a novel formulation that retains the smooth control of a long-acting basal with rapid-acting mealtime control from insulin aspart. This 2-component insulin retains the ultralow risk characteristics ...

  5. Senate panel questions Novo Nordisk CEO over decision to ...

    www.aol.com/senate-panel-questions-novo-nordisk...

    Long-acting insulins lengthen the time between injections and allow patients to maintain baseline blood glucose levels. More than 7 million U.S. patients use insulin products.

  6. Insulin analog - Wikipedia

    en.wikipedia.org/wiki/Insulin_analog

    This is an ultralong-acting insulin analogue developed by Novo Nordisk, which markets it under the brand name Tresiba. It is administered once daily and has a duration of action that lasts up to 40 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir). [5] [6]

  7. Novo Nordisk to discontinue Levemir insulin in U.S. market - AOL

    www.aol.com/news/novo-nordisk-discontinue...

    Novo has another long-acting insulin, Tresiba, on the market. "Novo Nordisk will phase out, then permanently discontinue Levemir in the U.S. on December 31, 2024," the company said in a statement.

  1. Ads

    related to: long acting insulin brands